Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2754582 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 6 Pages |
Abstract
BackgroundDespite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement.Materials and MethodsWe reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts.ResultsMulticycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer.ConclusionsConcerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Vijaya Raj Bhatt, Hagop Kantarjian, Jorge E. Cortes, Farhad Ravandi, Gautam Borthakur,